PDF
ePub
Citation
Print
Abstract
Transplantation has become an established treatment in many end-stage organ diseases and hematologic diseases. The survival rate after transplantation has greatly improved due to the development of newer immunosuppressive drugs bringing the issues of post-transplantation complications to light. Osteoporosis and osteoporosis-related fragility fractures are feared complications, greatly influencing the quality of life in transplant patients. In addition to the conventional risk factors for osteoporosis, post-transplantation osteoporosis is caused by factors related to end-stage organ disease prior to transplantation and immunosuppressive therapy after transplantation. Since the rate of bone loss in post-transplantation osteoporosis is thought to be at the greatest immediately following transplantation, early measures need to be taken to prevent and treat post-transplantation osteoporosis. Both conventional and newer therapeutics for osteoporosis are largely being studied and used in practice for the prevention and treatment of post-transplantation osteoporosis.
References
1). Stein E, Ebeling P, Shane E. Posttransplantation osteoporosis. Endocrinol Metab Clin North Am. 2007; 36:937–63. viii.
2). Kulak CA, Borba VZ, Kulak Júnior J, Shane E. Transplantation osteoporosis. Arq Bras Endocrinol Metabol. 2006; 50:783–92.
3). Cohen A, Shane E. Osteoporosis after solid organ and bone marrow transplantation. Osteoporos Int. 2003; 14:617–30.
4). Nisbeth U, Lindh E, Ljunghall S, Backman U, Fellström B. Increased fracture rate in diabetes mellitus and females after renal transplantation. Transplantation. 1999; 67:1218–22.
5). Compston JE. Osteoporosis after liver transplantation. Liver Transpl. 2003; 9:321–30.
6). Sokhi RP, Anantharaju A, Kondaveeti R, Creech SD, Islam KK, Van Thiel DH. Bone mineral density among cirrhotic patients awaiting liver transplantation. Liver Transpl. 2004; 10:648–53.
7). Carey EJ, Balan V, Kremers WK, Hay JE. Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: not just a cholestatic problem. Liver Transpl. 2003; 9:1166–73.
8). Aris RM, Neuringer IP, Weiner MA, Egan TM, Ontjes D. Severe osteoporosis before and after lung transplantation. Chest. 1996; 109:1176–83.
9). Shane E, Silverberg SJ, Donovan D, Papadopoulos A, Staron RB, Addesso V, et al. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease. Am J Med. 1996; 101:262–9.
10). Tschopp O, Boehler A, Speich R, Weder W, Seifert B, Russi EW, et al. Osteoporosis before lung transplantation: association with low body mass index, but not with underlying disease. Am J Transplant. 2002; 2:167–72.
11). Teramoto S, Matsuse T, Ouchi Y. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease. Am J Med. 1997; 103:334–6.
12). Shane E, Rivas MC, Silverberg SJ, Kim TS, Staron RB, Bilezikian JP. Osteoporosis after cardiac transplantation. Am J Med. 1993; 94:257–64.
13). Yao S, McCarthy PL, Dunford LM, Roy DM, Brown K, Paplham P, et al. High prevalence of early-onset osteope-nia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy. Bone Marrow Transplant. 2008; 41:393–8.
14). Schimmer AD, Minden MD, Keating A. Osteoporosis after blood and marrow transplantation: clinical aspects. Biol Blood Marrow Transplant. 2000; 6(2A):175–81.
15). van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int. 2006; 79:129–37.
16). Adachi JD. Glucocorticoid-induced osteoporosis. Osteoporos Int. 2009; 20(Suppl 3):S239–40.
17). Patschan D, Loddenkemper K, Buttgereit F. Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone. 2001; 29:498–505.
18). O'Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2004; 145:1835–41.
19). Weinstein RS, Chen JR, Powers CC, Stewart SA, Landes RD, Bellido T, et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest. 2002; 109:1041–8.
20). Epstein S. Posttransplantation bone disease: the role of immunosuppressive agents and the skeleton. J Bone Miner Res. 1996; 11:1–7.
21). Orcel P, Denne MA, de Vernejoul MC. Cyclosporin-A in vitro decreases bone resorption, osteoclast formation, and the fusion of cells of the monocyte-macrophage lineage. Endocrinology. 1991; 128:1638–46.
22). Movsowitz C, Epstein S, Fallon M, Ismail F, Thomas S. Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology. 1988; 123:2571–7.
23). Schlosberg M, Movsowitz C, Epstein S, Ismail F, Fallon MD, Thomas S. The effect of cyclosporin A administration and its withdrawal on bone mineral metabolism in the rat. Endocrinology. 1989; 124:2179–84.
24). Grotz WH, Mundinger FA, Gugel B, Exner V, Kirste G, Schollmeyer PJ. Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients. Transplantation. 1994; 58:912–5.
25). Ponticelli C, Aroldi A. Osteoporosis after organ transplantation. Lancet. 2001; 357:1623.
26). Grotz WH, Rump LC, Niessen A, Schmidt-Gayk H, Reichelt A, Kirste G, et al. Treatment of osteopenia and osteoporosis after kidney transplantation. Transplantation. 1998; 66:1004–8.
27). McIntyre HD, Menzies B, Rigby R, Perry-Keene DA, Hawley CM, Hardie IR. Long-term bone loss after renal transplantation: comparison of immunosuppressive regimens. Clin Transplant. 1995; 9:20–4.
28). Josephson MA, Schumm LP, Chiu MY, Marshall C, Thistlethwaite JR, Sprague SM. Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. Transplantation. 2004; 78:1233–6.
29). Stempfle HU, Werner C, Echtler S, Assum T, Meiser B, Angermann CE, et al. Rapid trabecular bone loss after cardiac transplantation using FK506 (tacrolimus)-based immunosuppression. Transplant Proc. 1998; 30:1132–3.
30). Park KM, Hay JE, Lee SG, Lee YJ, Wiesner RH, Porayko MK, et al. Bone loss after orthotopic liver transplantation: FK 506 versus cyclosporine. Transplant Proc. 1996; 28:1738–40.
31). Goffin E, Devogelaer JP, Depresseux G, Squifflet JP, Pirson Y. Osteoporosis after organ transplantation. Lancet. 2001; 357:1623.
32). Monegal A, Navasa M, Guañabens N, Peris P, Pons F, Martínez de Osaba MJ, et al. Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcif Tissue Int. 2001; 68:83–6.
33). Kulak CA, Borba VZ, Kulak Júnior J, Campos DJ, Shane E. Posttransplantation osteoporosis. Arq Bras Endocrinol Metabol. 2010; 54:143–9.
34). Briffa NK, Keogh AM, Sambrook PN, Eisman JA. Reduction of immunosuppressant therapy requirement in heart transplantation by calcitriol. Transplantation. 2003; 75:2133–4.
35). Lemire JM. Immunomodulatory role of 1,25-dihydroxy-vitamin D3. J Cell Biochem. 1992; 49:26–31.
36). Sambrook P, Henderson NK, Keogh A, MacDonald P, Glanville A, Spratt P, et al. Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Miner Res. 2000; 15:1818–24.
37). Stempfle HU, Werner C, Echtler S, Wehr U, Rambeck WA, Siebert U, et al. Prevention of osteoporosis after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation. 1999; 68:523–30.
38). Stempfle HU, Werner C, Siebert U, Assum T, Wehr U, Rambeck WA, et al. The role of tacrolimus (FK506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation. 2002; 73:547–52.
39). Ninkovic M, Love S, Tom BD, Bearcroft PW, Alexander GJ, Compston JE. Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation. J Hepatol. 2002; 37:93–100.
40). Aris RM, Lester GE, Renner JB, Winders A, Denene Blackwood A, Lark RK, et al. Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. Am J Respir Crit Care Med. 2000; 162(3 Pt 1):941–6.
41). Bianda T, Linka A, Junga G, Brunner H, Steinert H, Kiowski W, et al. Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate. Calcif Tissue Int. 2000; 67:116–21.
42). Pennisi P, Trombetti A, Giostra E, Mentha G, Rizzoli R, Fiore CE. Pamidronate and osteoporosis prevention in liver transplant recipients. Rheumatol Int. 2007; 27:251–6.
43). Hommann M, Abendroth K, Lehmann G, Patzer N, Kornberg A, Voigt R, et al. Effect of transplantation on bone: osteoporosis after liver and multivisceral transplantation. Transplant Proc. 2002; 34:2296–8.
44). Crawford BA, Kam C, Pavlovic J, Byth K, Handelsman DJ, Angus PW, et al. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2006; 144:239–48.
45). Kovac D, Lindic J, Kandus A, Bren AF. Prevention of bone loss in kidney graft recipients. Transplant Proc. 2001; 33:1144–5.
46). Jeffery JR, Leslie WD, Karpinski ME, Nickerson PW, Rush DN. Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate. Transplantation. 2003; 76:1498–502.
47). Koc M, Tuglular S, Arikan H, Ozener C, Akoglu E. Alendronate increases bone mineral density in longterm renal transplant recipients. Transplant Proc. 2002; 34:2111–3.
48). Giannini S, D'Angelo A, Carraro G, Nobile M, Rigotti P, Bonfante L, et al. Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res. 2001; 16:2111–7.
49). Kananen K, Volin L, Laitinen K, Alfthan H, Ruutu T, Välimäki MJ. Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate. J Clin Endocrinol Metab. 2005; 90:3877–85.
50). Tauchmanovà L, Ricci P, Serio B, Lombardi G, Colao A, Rotoli B, et al. Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation. J Clin Endocrinol Metab. 2005; 90:627–34.
51). Tauchmanovà L, Selleri C, Esposito M, Di Somma C, Orio F Jr, Bifulco G, et al. Beneficial treatment with risedronate in longterm survivors after allogeneic stem cell transplantation for hematological malignancies. Osteoporos Int. 2003; 14:1013–9.
52). Trombetti A, Gerbase MW, Spiliopoulos A, Slosman DO, Nicod LP, Rizzoli R. Bone mineral density in lung-transplant recipients before and after graft: pre-vention of lumbar spine posttransplantation-accelerated bone loss by pamidronate. J Heart Lung Transplant. 2000; 19:736–43.
53). Isoniemi H, Appelberg J, Nilsson CG, Mäkelä P, Risteli J, Höckerstedt K. Transdermal oestrogen therapy protects postmenopausal liver transplant women from osteoporosis. A 2-year follow-up study. J Hepatol. 2001; 34:299–305.
54). Cejka D, Benesch T, Krestan C, Roschger P, Klaushofer K, Pietschmann P, et al. Effect of teriparatide on early bone loss after kidney transplantation. Am J Transplant. 2008; 8:1864–70.
55). Hommann M, Kämmerer D, Lehmann G, Kornberg A, Kupper B, Daffner W, et al. Prevention of early loss of bone mineral density after liver transplantation by prostaglandin E1. Transplant Proc. 2007; 39:540–3.
XML Download